MedTrace Logo

FT538 in Subjects With Advanced Hematologic Malignancies

NCT04614636 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2023-09-21

No results posted yet for this study

Summary

This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Conditions

Interventions

DRUG

FT538

Experimental Interventional Therapy, Allogeneic Cell Therapy NK Cell

DRUG

Cyclophosphamide

Lympho-conditioning Agent

DRUG

Fludarabine

Lympho-conditioning Agent

DRUG

Daratumumab

Monoclonal Antibody, CD38, Anti-CD38

DRUG

Elotuzumab

Monoclonal Antibody

Sponsors & Collaborators

Principal Investigators

  • Fate Trial Disclosure · Fate Therapeutics, Inc

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-17
Primary Completion
2023-07-13
Completion
2023-08-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04614636 on ClinicalTrials.gov